CoChat

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Open access
Monge, Cecilia, Xie, Changqing, Myojin, Yuta, Coffman, Kelley, Hrones, Donna Mabry, Wang, Sophie, Hernandez, Jonathan M, Wood, Bradford J, Levy, Elliot B, Juburi, Israa, Hewitt, Stephen M, Kleiner, David E, Steinberg, Seth M, Figg, William D, Redd, Bernadette, Homan, Philip, Cam, Maggie, Ruf, Benjamin, Duffy, Austin G, Greten, Tim F · 2023 · Journal for ImmunoTherapy of Cancer
Cited by 75

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (anti-cytotoxic T-lymphocyte associated protein 4) in patients with standard chemotherapy refractory mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) in a phase I/II trial. Methods: Adult patients with histologically confirmed advanced pMMR mCRC, who had progressed on at least two prior lines of systemic chemotherapy were studied in four cohorts. Patients received four doses of PexaVec IV at a dose of 3×10 8 plaque forming units (pfu) (dose level 1) or 1×10 9 pfu (dose level 2) every 2 weeks. Twelve days after the first PexaVec administration, patients received either 1500 mg of durvalumab every 28 days alone or an additional single dose of 300 mg tremelimumab on day 1. Responses were assessed every 8 weeks by CT or MRI. AEs were recorded. The primary endpoints were safety and feasibility. Secondary endpoints included progression-free survival (PFS) and overall survival. Paired tumor samples and peripheral blood were collected to perform immune monitoring. Results: Thirty-four patients with mCRC enrolled on to the study: 16 patients in the PexaVec/durvalumab cohorts and 18 patients in the PexaVec/durvalumab/tremelimumab cohorts. Overall, the combination of PexaVec plus immune checkpoint inhibitors did not result in any unexpected toxicities. Most common toxicities observed were fever and chills after PexaVec infusion. Two cases of grade 3 colitis, one case of a grade 2 myositis and one case of grade 3 hypotension resulted in discontinuation of immune checkpoint inhibitor and PexaVec treatment, respectively. The median PFS in the PexaVec/durvalumab/tremelimumab cohorts was 2.3 months (95% CI: 2.2 to 3.2 months) vs 2.1 months (95% CI: 1.7 to 2.8 months; p=0.57) in the PexaVec/durvalumab cohorts. Flow cytometry analysis of peripheral blood mononuclear cells revealed an increase in Ki67+CD8+ T cells on treatment. Conclusion: PexaVec in combination with durvalumab and tremelimumab is safe and tolerable. No unexpected toxicities were observed. The combination of PexaVec/durvalumab/tremelimumab demonstrated potential clinical activity in patients with pMMR mCRC, but further studies are needed to identify the predictive biomarkers. Trial registration number: NCT03206073.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2022-005640

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 75

Metadata

Authors
Monge, C., Xie, C., Myojin, Y., Coffman, K., Hrones, D. M., Wang, S., Hernandez, J. M., Wood, B. J., Levy, E. B., Juburi, I., Hewitt, S. M., Kleiner, D. E., Steinberg, S. M., Figg, W. D., Redd, B., Homan, P., Cam, M., Ruf, B., Duffy, A. G., & Greten, T. F.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2023-02
Volume
11
Issue
2
Pages
e005640
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4319593205
Cited by
75
References
10
FWCI
7.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. https://app.cochat.ai/papers/10.1136/jitc-2022-005640
The paper
Monge, C., Xie, C., Myojin, Y., Coffman, K., Hrones, D. M., Wang, S., Hernandez, J. M., Wood, B. J., Levy, E. B., Juburi, I., Hewitt, S. M., Kleiner, D. E., Steinberg, S. M., Figg, W. D., Redd, B., Homan, P., Cam, M., Ruf, B., Duffy, A. G., & Greten, T. F. (2023). Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-005640

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.